XFOR — X4 Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $317.27m
- $186.06m
- $35.11m
U.S. STOCKS ON THE MOVE-Tesla, Apple, Domino's
Brief: X4 Pharmaceuticals Announces FDA Approval Of Xolremdi Capsules, First Drug Indicated In Patients With Whim Syndrome
X4 Pharmaceuticals rises as US FDA approves immunodeficiency therapy
US FDA approves X4 Pharmaceuticals' therapy for immunodeficiency disease (updated)
US FDA approves X4 Pharmaceuticals' drug for immunodeficiency disease
X4 Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: X4 Pharmaceuticals Q4 EPS USD -0.1
X4 Pharmaceuticals Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: X4 Pharmaceuticals - Believes It Has Sufficient Funds To Support Company Operations Into 2025
Brief: X4 Pharmaceuticals Q3 EPS USD -0.01
U.S. STOCKS ON THE MOVE-Leidos, EcoLab, Shutterstock
U.S. STOCKS ON THE MOVE-GE HealthCare, Pfizer, Ford Motor
X4 Pharma jumps as FDA accepts marketing application for immune treatment
Brief: X4 Pharmaceuticals Announces FDA Acceptance With Priority Review Of U.S. NDA For Mavorixafor In Whim Syndrome
X4 Pharmaceuticals Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: X4 Pharmaceuticals Submits Application To U.S. FDA For Mavorixafor In WHIM Syndrome
X4 Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary